N/A
Completed N=20
Design Improvements With SONNET 3
Hearing Loss, Sensorineural
Source: ClinicalTrials.gov NCT06597747 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcomePrimary: Participants Reporting Improvement With SONNET 3 Design — 20 Participants
Summary
Measuring user-reported satisfaction with the latest behind-the-ear (BTE) audio processor model.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants Reporting Improvement With SONNET 3 Design |
20 | — |
| SECONDARY Audiologist Satisfaction Ratings |
5.4; 5.5 | — |
Eligibility Criteria
Inclusion Criteria
- Implanted with a MED-EL cochlear implant in at least one ear
- ≥ 12 months since activation of the MED-EL audio processor
- Consistently using a SONNET (EAS) or SONNET 2 (EAS) Audio Processor
- Ability to complete all study procedures
- Participant and parental (if applicable) commitment to comply with all study procedures for the duration of the study
Exclusion Criteria
- Evidence that hearing loss is retrocochlear in origin
- Unable to provide reliable feedback during cochlear implant programming
- Skin or scalp condition precluding use of the study device
- Unrealistic participant or parent (if applicable) motivation or expectations
- Participants without a stable fitting map at enrollment e.g., due to changes in hearing, global health status, etc.
Data sourced from ClinicalTrials.gov (NCT06597747). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.